# US 2021/0061849 A1 · Neuroactive steroids, compositions, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061849 A1
- Document ID: US20210061849A1
- Status: Published application
- Kind: A1
- Application number: 17/094,783
- Filed: 2020-11-10
- Published: 2021-03-04
- Earliest claimed: 2014-05-29
- Assignees: Sage Therapeutics, Inc.
- Applicants: Sage Therapeutics, Inc.
- Inventors: Gabriel Martinez Botella; Boyd L. Harrison; Albert Jean Robichaud; Francesco G. Salituro; Richard Thomas Beresis
- Web page: https://patentgrep.com/patent/US20210061849A1

## CPC

- C07J 43/003: {not condensed}
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- C07J 7/0085: {by an halogen atom}
- C07J 1/0022: {the substituent being an OH group free esterified or etherified}
- C07J 1/0059: {substituted in position 17 by a keto group}
- C07J 7/002: {not substituted in position 16}
- C07J 7/007: {not substituted in position 17 alfa}
- C07J 13/007: {with double bond in position 17 (20)}
- C07J 21/00: Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J 31/006: {not covered by C07J31/003}
- C07J 71/001: {Oxiranes}
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method of generating a compound of formula (SI-4):
or a pharmaceutically acceptable salt thereof, comprising
(a) reacting compound
SI with 5-methyl-1H-tetrazole in the presence of K2CO3 and a solvent to generate the compound of formula (SI-4).

### Claim 36 (depends on 35)

The method of claim 35, wherein step (a) is performed at a temperature of about 60° C.

### Claim 37 (depends on 35, 36)

The method of claim 35 or claim 36, further comprising
(b) reacting compound
SI-F1 with HBr and bromine to generate compound SI.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the solvent of step (a) is THF.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, further comprising
(c) reacting compound
SI-E with sodium in dry methanol to generate the compound SI-F1.

### Claim 40 (depends on 39)

The method of claim 39, further comprising
(d) reacting compound
SI-D with DMP in a solvent system comprising water and CH2Cl2 to generate the compound SI-E.

### Claim 41 (depends on 39)

The method of claim 39, wherein the solvent system comprises CH2Cl2 saturated with water.

### Claim 42 (depends on 40, 41)

The method of claim 40 or claim 41, wherein the reaction of step (d) is performed under stirring conditions.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40-42, further comprising
(e) reacting compound
SI-C with trimethylsulfonium iodide and sodium hydride in a solvent to generate compound SI-D.

### Claim 44 (depends on 43)

The method of claim 43, wherein the solvent of step (e) is DMSO.

### Claim 45 (depends on 43, 44)

The method of claim 43 or claim 44, wherein step (e) is performed under stirring conditions at room temperature.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43-45, further comprising
(f) reacting compound
SI-B with HCl in a solvent to generate the compound SI-C.

### Claim 47 (depends on 46)

The method of claim 46, wherein the HCl of step (f) is reacted at a concentration of 2M.

### Claim 48 (depends on 46, 47)

The method of claim 46 or 47, wherein step (f) is performed under stirring conditions for about 12 hours.

### Claim 49 (depends on 46, 47, 48)

The method of any one of claims 46-48, wherein step (f) is performed at room temperature.

### Claim 50 (depends on 46, 47, 48, 49)

The method of any one of claims 46-49, further comprising
(g) reacting compound
SI-A with a borane-tetrahydrofuran complex to generate the compound SI-B.

### Claim 51 (depends on 50)

The method of claim 50, wherein step (g) is performed in the presence of NaOH.

### Claim 52 (depends on 51)

The method of claim 51, wherein the NaOH is provided as about 10% aqueous NaOH.

### Claim 53 (depends on 50, 51)

The method of claim 50 or 51, wherein step (g) is performed in the presence of H2O2.

### Claim 54 (depends on 53)

The method of claim 53, wherein the H2O2 is provided as an about 30% aqueous solution of H2O2.

### Claim 55

A method of generating a compound of formula (SI-4):
or a pharmaceutically acceptable salt thereof, comprising
(a) reacting compound
SI with 5-methyl-1H-tetrazole in the presence of K2CO3 and a solvent to generate the compound of formula (SI-4);
(b) reacting compound
SI-F1 with HBr and bromine to generate compound SI; and
(c) reacting compound
SI-E with sodium in dry methanol to generate the compound SI-F1.

### Claim 56 (depends on 55)

The method of claim 55, wherein step (a) is performed at a temperature of about 60° C.; and the solvent of step (a) is THF.
